

This is a “preproof” accepted article for *Journal of Clinical and Translational Science*.

This version may be subject to change during the production process.

10.1017/cts.2023.622

## **Quantitative Assessment of the Impact of Standard Agreement Templates on Multisite Clinical Trial Start Up Time**

Colleen E. Lawrence, PhD<sup>1</sup>, Virginia (Nickie) M. Bruce, BS<sup>2</sup>, Libby D. Salberg, JD<sup>3</sup>, Terri Edwards, RN<sup>1</sup>, Casi Morales, JD<sup>4</sup>, Marisha Palm, MSc, PhD<sup>5</sup>, and Gordon R. Bernard, MD<sup>1,6</sup>

<sup>1</sup>Vanderbilt Institute for Clinical and Translational Research (VICTR), Vanderbilt University Medical Center, Nashville, TN, United States

<sup>2</sup>Office of Legal Contract Administration, Mayo Clinic, Rochester, MN, United States

<sup>3</sup>Office of Contracts Management, Vanderbilt University Medical Center, Nashville, TN, United States

<sup>4</sup>Clinical Trials Office, University of Utah, Pediatrics, Salt Lake City, UT, United States

<sup>5</sup>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States

<sup>6</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States

**Corresponding author:** Colleen E. Lawrence, Vanderbilt University Medical Center, 2525 West End Ave, Nashville, TN, 37203 USA. (Email: colleen.lawrence@vumc.org)

**Conflicts of Interest:** The authors declare that they have no conflicts of interest.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

## ABSTRACT

Contracting delays remain a challenge to the successful initiation of multisite clinical research in the US. The Clinical and Translational Science Awards (CTSA) Contracts Processing Study showed average contract negotiation duration of >100-days for industry-sponsored or investigator-initiated contracts. Such delays create enormous costs to sponsors and to patients waiting to use new evidence-based treatments. With support from the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS), the [Accelerated Clinical Trial Agreement \(ACTA\)](#) was developed by 25 major academic institutions and medical centers engaged in clinical research in collaboration with the University-Industry Demonstration Partnership (UIDP) and with input from pharmaceutical companies. The ACTA also informed the development of subsequent agreements, including the Federal Demonstration Partnership Clinical Trial Subaward Agreement (FDP CTSA); both ACTA and the FDP-CTSA are largely non-negotiable agreements that represent pre-negotiated compromises in contract terms agreed upon by industry and/or medical center stakeholders. When the involved parties agree to use the CTSA-developed and supported standard agreement templates as a starting point for negotiations, there can be significant time savings for trials. Use of the ACTA resulted in an average savings of 48 days and use of the FDP-CTSA saved average of 57 days of negotiation duration.

**Keywords:** *Contracts; Standard Agreements; ACTA; CTSA Consortium; Clinical Research Management*

## **Introduction**

Launching multi-center clinical trials is complex and time-consuming. Review and negotiation for research-related agreements is a primary contributor and a key opportunity for improved efficiency in trial startup.<sup>1,2</sup> Regardless of funding source, new studies may require the review and execution of several agreements (e.g., confidential disclosure agreement, clinical trial agreement). Estimates of the cost due to delays in contracting for a pharmaceutical trial sponsor range from \$600,000 to \$8 million per day of delay when including the cost of lost sales of a potential drug.<sup>3</sup> Additionally, lags in startup have a significant human cost, delaying the evaluation and prescribing of potential new treatments.<sup>4</sup> Data from the 2010 Clinical and Translational Science Awards (CTSA) Contracts Processing Study revealed that negotiating contract terms for a clinical trial agreement required a mean time of 55 days, but that use of a master agreement could reduce the mean for full negotiation to 22 days.<sup>5</sup> A master clinical trial agreement (“Master Agreement”) is a formal agreement made in advance between an industry sponsor and a site that establishes core terms for clinical trials initiated between the parties. Each study under the Master Agreement can be initiated with a simple study specific letter acknowledging the Master Agreement and identifying the study specific budget and protocol without requiring any negotiation of legal terms between the parties.

## **Why is a Sponsor Master Agreement not enough?**

Sponsor-specific Master Agreements continue to be used, despite limited data to illustrate their level of uptake and efficacy. Industry sponsors have unique Master Agreements that are pre-negotiated with each of their major partner sites. Negotiating a sponsor Master Agreement can take many months, or in some cases years, and the agreements may have limited effective periods of 3-5 years.<sup>6</sup> A sponsor-specific master agreement can be very effective but has drawbacks associated with being costly and time consuming at start-up. The ACTA can add value in situations where the cost and effort to craft a Master are not worth it to the involved parties or in cases where resources may be limited.

## **Leading Master Agreement innovations: The CTSA Program and the Trial Innovation Network**

Significant national efforts have been made to address issues around research-related agreements.<sup>7,8</sup> The CTSA Program and the Trial Innovation Network (TIN), supported by the National Center for Advancing Translational Science (NCATS), aim to transform biomedical research processes to increase the speed by which discoveries are translated into practice.<sup>9–11</sup> The TIN is a collaborative initiative within the CTSA Program and is comprised of three key partners – the >60 CTSAAs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).<sup>10,11</sup> As part of their changes to address scientific and methodological challenges, the CTSA Program and TIN, were charged with overcoming administrative and institutional organizational barriers.<sup>9</sup> Tackling issues with contracting delays became part of the CTSA mission in 2012, when NCATS and the CTSA Program launched the Accelerated Research Agreements (ARA) Initiative, whose mission is to provide agreements that are acceptable to participating institutions and organizations in an effort to expedite the study initiation process.<sup>12</sup> This initiative was furthered in 2016 with the launch of the TIN Standard Agreements workgroup.

The ARA Initiative and the Standard Agreements workgroup sought to promote a model for creating standard agreement templates that most institutions and many sponsors could accept, thereby negating the need for duplicative and time-consuming negotiations. This communication describes efforts to develop and refine solutions and focuses on the two most heavily used standard agreements stemming from these initiatives, the Accelerated Clinical Trial Agreement (ACTA) and the Federal Demonstration Partnership Clinical Trial Subaward Agreement (FDP-CTSA).

### **Developing and refining a solution: The ACTA**

Industry funds nearly six-fold more clinical trials than federal sources and accounts for roughly 70% of dollars spent on clinical drug trials.<sup>13,14</sup> The ACTA focused on multisite, industry-sponsored trials and was the first template to come from the ARA Initiative. The goal for the ACTA was to create a straightforward document which clearly sets forth the contractual obligations of both parties in language that includes pre-agreed upon compromises to contract

terms. The ACTA was developed by a workgroup comprised of legal and contracting experts from 25 major academic institutions and medical centers, engaged in clinical and translational research, in collaboration with the University-Industry Demonstration Partnership (UIDP)<sup>15</sup> and with input from several pharmaceutical companies (Workgroup members: <https://ara4us.org/acta/work-group-membership/>).

The ACTA differed from other concurrent standard agreement efforts, including MAGI (Model Agreements & Guidelines International) and TransCelerate, in that 1) it focused on creating a full draft contract rather than a term library; 2) the final agreement was based on terms that both parties usually end up agreeing to after multiple rounds of negotiation (i.e., compromised approach); 3) the agreement was created with support from both industry and academic partners; and 4) this effort received significant NIH support, as well as organized outreach and promotion.<sup>16</sup>

In brief, the ACTA was developed by creating a list of 28 terms specific to clinical trial contracting. The terms were sent to workgroup members to prioritize and rank from least to most difficult to negotiate. The workgroup defined the common position of academic institutions and industry for each of the most challenging terms. Using the preferred positions of each party as the starting point, the workgroup proceeded to craft compromise language for the terms being included in the ACTA standard agreement. The most difficult to negotiate were Insurance, Confidential Information, Publication, Limitation of Liability, Subject Injury, Data Use/Ownership, Intellectual Property, and Indemnification (See **Table 1**). To arrive at final terms, the workgroup utilized contract language that was often the final position arrived upon in previous contracts after negotiation – i.e., starting with the most frequent compromise position. For more challenging terms, industry and academic partners shared their concerns related to risks and local context/laws to construct language that addressed most concerns even if it could not completely mitigate all risk. Industry sponsors, organizations, and academic institutions reviewed final draft language with extensive discussions to arrive at the final agreement with terms that were acceptable, if not completely satisfactory, to all parties.

Following term harmonization and development of the ACTA, the standard agreement was reviewed by a larger workgroup with representatives from each of the >60 CTSA and piloted with five studies from five unique sponsors across ~40 sites to look for serious flaws in the document. There were no substantive changes and after several months of socializing the terms through meetings with the CTSA, the ACTA was published in October 2014.

The ACTA continues to be refined by a small workgroup composed of many of the original ACTA workgroup members to keep pace with changes in federal guidelines and the new methodologies being used to conduct clinical trials (e.g., remote monitoring, electronic consenting). From the genesis of the ACTA in its initial iteration to its current version, the terms have evolved to address existing or emerging issues from the sponsors and sites (e.g., updated record retention language inclusion of CRO and affiliate assignment language) and to include new language that reflects the changes in the conduct of clinical trials (e.g., data security and cloud-based portals to house participant data, the Sunshine Act<sup>17</sup>, Human Research Protection Program Accreditation standards). The newest version of the ACTA is also more clearly delineated to be used with Phase II studies and beyond. After establishing a model for creating the ACTA template, additional agreements were developed (See **Table 2**) to address other common scenarios in clinical trial conduct that require specific agreements, such as investigator-initiated trials and confidential disclosure agreements. Sites can register to use any or all the template agreements as appropriate to their institution's policies and needs.

### **Quantifying the impact of standard agreements**

The support and CTSA resources allocated to developing standard agreements led to the prioritization of capturing metrics of usage and potential time savings for the various template agreements. However, there were several challenges in collecting metrics due to a lack of harmonization for contracting data elements. Specifically, data points such as  $T_0$  (the initial time identifying the start of the contracting process) and  $T_{\text{FINAL}}$  for contract negotiations are often defined differently across centers. Recognizing these limitations, the group also focused its data collection on standard agreement usage rates along with assessing what materials and methods existed at various sites to promote and educate on standard agreements.

### *CTSA usage of ACTA*

The ACTA workgroup developed a REDCap-based survey to assess usage and potential time savings across the CTSA and other institutions associated with the ARA Initiative.<sup>18</sup> Survey elements included use of the ACTA and average calendar days from the date the package (defined as all necessary documents needed to begin the process) was received to the date all terms were negotiated (defined as terms complete but may be waiting on IRB or budget) for the ACTA as compared with non-standard agreement templates. Two separate rounds of survey data were collected. The first round of data was collected during a 24-month period from 2015-2017. The survey was sent to the points of contact for all CTSA and organizations who supported the original development and review of the ACTA as part of the larger ACTA workgroup. There were 55 organizations and CTSA institutions that responded and reported that the ACTA was used ~90 times with an average time savings for full negotiation of 40 days. Contracting processes are highly variable in nature given the range of factors that can impact their full execution, and estimates collected in the survey reflected this variability, ranging from seven days to six months. The total number of studies conducted across the more than 55 organizations and institutions were not captured; therefore, we are not able to provide a denominator for 2015-2017 use.

In 2021, a second survey was sent to 13 CTSA sites active in the smaller ACTA workgroup that helped draft the original ACTA and who completed the initial round 1 survey, requesting information on use of standard agreements negotiated during 2019-2021, with specific emphasis on negotiation time in days for the ACTA versus no standard agreement (See **Figure 1**). The follow-up survey explored whether ACTA usage had increased over time. Seven organizations responded with complete data sets for ACTA usage and negotiation times with and without the ACTA or standard agreement. The ACTA was used 122 times across the seven sites and demonstrated an average time savings for full negotiation of 55 days when compared to negotiations without the ACTA or standard agreement.

To date, **>350** research sites, including academic medical centers, universities, hospitals, physician practices, and industry sponsors, have agreed to the terms of the ACTA and to accept it

without revision. In addition, the ACTA agreement has been downloaded >1,500 unique times from ara4us.org.

### **Adapting this solution for federally funded clinical trials: The FDP-CTSA**

With the industry-focused ACTA work progressing, NCATS, CTSA leadership and the FDP pivoted to address the nuances associated with a federal sub-award agreement template for clinical trials. In June 2015, a new workgroup comprised of representatives from a subgroup of CTSAAs, the original ACTA workgroup, and FDP member institutions was convened to focus on drafting a standard federal sub-award agreement.<sup>19</sup> The sub-award template was premised upon: use of an NIH Sponsor, Fixed Price, domestic enrolling sites, compliance with all federal regulations, adherence to ACTA terms when possible, and allowance for the addition of study-specific terms. The resulting standard agreement, the FDP-CTSA, was officially approved for use by the CTSA stakeholders, the NIH, and the FDP in August 2016 and updated again in 2020 when the FDP amended their template to reflect changes in federal guidelines.<sup>20</sup>

National adoption of the FDP-CTSA was furthered in 2016 when the TIN was launched. As part of its innovations, the TIN adapted the FDP-CTSA for use by the network and its standard agreements initiative to accelerate study start up across CTSA sites and their affiliates. The TIN workgroup used the FDP-CTSA as a starting point and made edits to terms within Attachment 2B (as allowed by the FDP) to better align with the needs of TIN studies. Attachment 2B contains study or network specific special terms and conditions. This template is officially known as the FDP-CTSA Trial Innovation Network Standard Agreement (“TIN Standard Agreement”).

Once completed, the workgroup sent the TIN Standard Agreement to all CTSAAs in the network and requested that each site register its acceptance of the standard agreement with the expectation that use of the agreement would reduce negotiation delays and allow for fast tracking of review once an actual study was issued. Only 2 CTSA sites did not register to use the TIN Standard Agreement. Ten CTSA affiliates also registered to use the agreement indicating their willingness to use this document as a starting point for contract negotiations in TIN studies.



### *TIN usage of FDP-CTSA*

The TIN gathered standard agreement metrics in those circumstances when the TIN FDP-CTSA was used in a multisite trial with a TIC (i.e., Duke, Utah) serving as the coordinating center (See **Figure 2**). The use of a designated coordinating center allowed for control of more variables in the contracting process, including consistency in defining which standard agreements would be used for contracting.

Six multi-center studies were identified who were awarded (and utilized) Standard Agreement services wherein a TIC acted as the study coordinating center and facilitated the contracting process using the TIN FDP-CTSA Standard Agreement (See **Figure 2**). There was a clear dichotomy across the studies with three studies having median days for negotiation at <46 days (median = 41, 46, 46), and the remaining three studies taking 64 days to well over 100 days for median negotiation time. Delays in negotiation were generally related to nuances of the associated studies rather than requests to change template language including one study being the first TIN study to use the new TIN FDP-CTSA (median = 64), another study had issues with the Study Drug term as several sites had concerns with the version of drug being provided by the industry sponsor (median = 109), and one study protocol was written by an EX-US sponsor which led to a flow down of General Data Protection Regulation (GDPR – regulation in European Union for protection and privacy) that was a required as a separate attachment to the agreement (median = 151).

### **Standard agreements and TIN-supported COVID-19 studies**

Four COVID-19 studies received TIN support and illustrate recent use cases for multi-site studies using a standard agreement template: ACTIV-1 (NCT04593940), ACTIV-4 Host Tissue/Novel Experimental COVID Therapies Affecting Host Response (ACTIV-4HT/NECTAR - NCT04924660), ACTIV-6 (NCT05736861), and Passive Immunity for Our Nation (PassItOn - NCT04362176). The smallest study had 28 sites (accrual goal of 1,000 participants) and the largest study had 74 sites (accrual goal of 15,000 participants). By using a standard agreement (e.g., FDP-CTSA or similar) the studies demonstrated significant time savings in average days to full contract execution across all study sites as compared to historical data. ACTIV-4HT/NECTAR had the longest average time to full contract execution with 75 days versus 103

days from historical data, and PassItOn had the shortest average time at 16 days.<sup>5</sup> This equates to time savings of 27 to 87 days which exceeds what would be expected for full contract execution with a non-master agreement, even when taking into consideration that some of this time savings is attributable to the prioritization of COVID-19 trials (which included putting other non-COVID studies on hold).

## **Lessons learned**

### *Challenges, limitations, and unanticipated outcomes*

Despite challenges to obtaining quality data on standard agreement usage, efforts have been made to assess usage of the ACTA and FDP-CTSA. Notably, our findings from the 2015-2017 CTSA survey of ACTA usage align with results from the University of California, Biomedical Research, Acceleration, Integration, and Development (UC BRAID) study, in which use of standard agreements was found to reduce negotiation time to an average of 39 days as compared to 73 days without a standard agreement.<sup>21</sup>

In addition to limitations with metrics collection, it should be noted that there are several potential confounders that exist within our standard agreements data including size of the institution and contracting office, number of studies conducted at a site per year, and inclusion of international sites among others. Future work should be done to understand how these variables impact the standard agreement process and negotiation time.

An unanticipated outcome of the ARA initiative is the use of modified standard agreements. While the intent of the initiative was for sites to use the standard agreements in their unmodified form, many sites have found success with using the ARA templates as starting points for negotiations. For example, some sites may be unable to use all the ACTA terms, so they use a modified ACTA (aka “MACTA”) in which negotiations are focused on a few specific terms rather than the whole agreement. Section 8, “Inventions, Discoveries, and Patents” is the section most often modified by ACTA users and is the one which requires the most review when Phase I studies seek to use the agreement. To avoid confusion, sites using the MACTA are asked to remove the ACTA moniker as that term is exclusively for the unmodified version.

There is anecdotal evidence of time savings when using the MACTA, however it is difficult to measure as many sites do not routinely track use of the MACTA. MACTA data collected from Mayo Clinic and University of Utah between 2019-2021 shows that the MACTA was used 36 times at Mayo for an average agreement turnaround time of 28 days and 30 times at University of Utah for an average turnaround time of 58 days.

### *Dissemination*

Dissemination and education are key to supporting and streamlining standard agreements. The virtual home for the ARA initiative is the [ara4us.org](http://ara4us.org) website, where interested research organizations can obtain more information about the initiative and follow its progress.<sup>12</sup> The website allows any organization to download the latest versions of the ARA initiative's templates, register to use individual agreements, see partnering sites, and identify workgroup members who contributed to the development of each agreement.<sup>12</sup> Registering for an agreement indicates that the registering institution would be willing to use that agreement and that the institution can be listed as an ARA participating organization on the website. Registration does not obligate an entity to use the standard agreement but rather allows for institutions and sponsors to view the website to determine potential parties to participate in upcoming studies and identify points of contact for outreach.

The ARA initiative has conducted outreach to research professionals and administrators, including MAGI, National Council of University Research Administrators (NCURA), and Society of Research Administrators (SRA), to raise awareness regarding the ACTA, FDP-CTSA, and other standard agreements. Additional education around the ARA initiative, the template agreements, and sites using them, is encouraged at the local level for onboarding new staff. Some sites have created processes to move those studies using standard agreements to the front of the contracting queue to promote adoption.

### *Examples of Best Practices*

A study of contract processes across Mayo Clinic sites in Minnesota, Florida, and Arizona provided further insight on strategies to help streamline contracting. In addition to utilizing the ACTA, the centers created methods to eliminate silos between business units, thereby allowing

parallel processes such as IRB review, contracting, and budgeting to occur and reduce delays.<sup>22</sup> The group also found that assigning a trained project manager to facilitate each trial through the activation processes (i.e., contract, protocol, budget, IRB) led to the greatest reduction in startup delays.<sup>22</sup>

The UC BRAID standard agreement study echoed some of the best practices identified by Mayo, specifically engaging in parallel processes and breaking down silos between business units. The group went further to say this could be accompanied by systematic and transparent collection of key metrics related to each step of site activation.<sup>21</sup> The group also suggested the need for developing shared technology such as databases or platforms for storing key metrics and clinical trial information that could be accessed across departments, thereby reducing redundant efforts and promoting parallel processes.<sup>21</sup>

Taken as a whole, these best practices suggest that successful optimal implementation of standard agreement templates and faster study activation requires cross-departmental institutional commitment. Centers must make a business decision to support collaborative streamlining efforts across relevant departments. The ACTA provides an excellent framework and centerpiece for coordinating these efforts.

## **Conclusions**

Mounting evidence in the literature and across the CTSA Program demonstrates time and labor savings from use of standard agreement templates. The CTSA is in a unique position to help motivate and mobilize contracting offices across the consortium to gather common metrics associated with the contracting process and to help determine and share best practices. Future directions for this work should include developing harmonized contracting metrics, gathering data from across the CTSA, continuing education and outreach efforts, and embedding best practices in standard agreements usage within various groups and then assessing impact. Additionally, ever-changing regulations (e.g., newly required telecommunications language) and the impact of the pandemic on the way clinical trials are conducted and monitored will necessitate review and updating of the ARA initiative's standard agreement templates.

## Acknowledgements

The authors extend their sincere thanks to all the members of the ACTA large and small workgroup as well as Trial Innovation Center standard agreement experts for their contributions to developing and supporting the template documents, as well as in metrics collection.


This project was supported by awards: VUMC CTSA (UL1 TR002243), and the Trial Innovation Centers (U24TR001608, U24TR001597, and U24TR001609) from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

## References

1. Lai J, Forney L, Brinton DL, Simpson KN. Drivers of Start-Up Delays in Global Randomized Clinical Trials. *Ther Innov Regul Sci*. 2021 Jan;55(1):212–227. PMID: PMC7505220
2. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. *J Clin Oncol Off J Am Soc Clin Oncol*. 2006 Oct 1;24(28):4545–4552. PMID: 17008693
3. Ltd JW& S, The Atrium SG, Chichester, PO19 8SQ, Tel : 01243 779777, Fax : 01243 770421. Clinical trials and their patients: The rising costs and how to stem the loss | Pharmafile [Internet]. [cited 2023 Jan 3]. Available from: <https://www.pharmafile.com/news/511225/clinical-trials-and-their-patients-rising-costs-and-how-stem-loss>
4. The Cost of Delaying A Trial | Pharmasols [Internet]. [cited 2021 Nov 1]. Available from: <https://pharmasols.com/news/april-2021/the-cost-of-delaying-a-trial/>
5. Kiriakis J, Gaich N, Johnston SC, Kitterman D, Rosenblum D, Salberg L, Rifkind A. Observational study of contracts processing at 29 CTSA sites. *Clin Transl Sci*. 2013 Aug;6(4):279–285. PMID: PMC3740442

6. Master & Template Agreements [Internet]. [cited 2022 Apr 5]. Available from: <https://research.ouhsc.edu/Research-Administration/Industry-Research/Clinical-Resources/Master-Template-Agreements>
7. Standardizing CTAs: International Efforts. *Appl Clin Trials* [Internet]. MJH Life Sciences; 2005 Jan 31 [cited 2022 Dec 27]; Available from: <https://www.appliedclinicaltrialsonline.com/view/standardizing-ctas-international-efforts>
8. Clinical Trial Agreements [Internet]. CDG Whitepapers. [cited 2022 Dec 27]. Available from: [https://clinicaldevice.typepad.com/cdg\\_whitepapers/2011/09/clinical-trial-agreements.html](https://clinicaldevice.typepad.com/cdg_whitepapers/2011/09/clinical-trial-agreements.html)
9. Califf RM, Berglund L, Principal Investigators of National Institutes of Health Clinical and Translational Science Awards. Linking scientific discovery and better health for the nation: the first three years of the NIH's Clinical and Translational Science Awards. *Acad Med J Assoc Am Med Coll*. 2010 Mar;85(3):457–462. PMID: PMC4552187
10. Wilkins CH, Edwards TL, Stroud M, Kennedy N, Jerome RN, Lawrence CE, Kusnoor SV, Nelson S, Byrne LM, Boone LR, Dunagan J, Israel T, Rodweller C, Drury B, Kost RG, Pulley JM, Bernard GR, Harris PA. The Recruitment Innovation Center: Developing novel, person-centered strategies for clinical trial recruitment and retention. *J Clin Transl Sci*. 2021;5(1):e194. PMID: PMC8634298
11. Bernard GR, Harris PA, Pulley JM, Benjamin DK, Michael J, Ford DE, Hanley DF, Selker HP, Wilkins CH. A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network. *J Clin Transl Sci*. 2018 Aug;2(4):187–192. PMID: PMC6474372
12. ARA4US [Internet]. [cited 2021 May 20]. Available from: <https://www.ara4us.org/>
13. Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. *JAMA*. 2015 Dec 15;314(23):2566–2567. PMID: PMC4919115
14. Beal K, Dean J, Chen J, Dragaon E, Saulino A, Collard CD. Budget negotiation for industry-sponsored clinical trials. *Anesth Analg*. 2004 Jul;99(1):173–176. PMID: 15281525

15. UIDP | Innovative Approaches to U-I Collaboration [Internet]. UIDP. [cited 2023 Apr 5]. Available from: <https://uidp.org/>
16. Common Language Evaluation and Reconciliation (CLEAR) – Society for Clinical Research Sites [Internet]. [cited 2023 Jan 6]. Available from: <https://myscrs.org/common-language-evaluation-and-reconciliation-clear/>
17. Sen. Grassley C [R I. S.301 - 111th Congress (2009-2010): Physician Payments Sunshine Act of 2009 [Internet]. 2009 [cited 2023 Apr 5]. Available from: <http://www.congress.gov/>
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009 Apr;42(2):377–381. PMID: PMC2700030
19. FDP Member Institutions - The Federal Demonstration Partnership [Internet]. [cited 2021 Nov 2]. Available from: <https://thefdp.org/default/about/fdp-member-institutions/>
20. Branch NSC and O. NIH and Other Federal Guidelines & Policies for Clinical Research [Internet]. National Institute of Arthritis and Musculoskeletal and Skin Diseases. NIAMS; 2017 [cited 2023 Apr 5]. Available from: <https://www.niams.nih.gov/grants-funding/conducting-clinical-research/trial-policies-guidelines-templates/nih-federal-guidelines>
21. Tran T, Bowman-Carpio L, Buscher N, Ford JJ, Jenkins E, Kalay HN, Nakazono T, Orescan H, Sak R, Shin I, Davidson P. Collaboration in Action: Measuring and Improving Contracting Performance in the University of California Contracting Network. *Res Manag Rev.* 2017;22(1):28–41. PMID: PMC6029617
22. Watters JT, Pitzen JH, Sanders LJ, Bruce V (Nickie) M, Cornell AR, Cseko GC, Grace JS, Kwon PS, Kukla AK, Lee MS, Monosmith MD, Myren JD, Kottschade RS, Shaft MN, Weis J (Jenny) A, Welter JC, Bharucha AE. Transforming the Activation of Clinical Trials. *Clin Pharmacol Ther.* 2018 Jan;103(1):43–46. PMID: PMC5774626




**Figure 1.** Average negotiation time in days for ACTA/standard agreements and non-standard agreements at select CTSA sites from 2019-2021. The ACTA was used 122 times during this period across the seven reporting sites with an average time savings of ~55 days compared to no ACTA or Master Agreement.

\* Negotiation time less than one day

‡ This site included sponsor review time in its metrics which accounts for a significant portion of the negotiation time.



Use of TIN FDP-CTSA Standard Agreement for Select TIN Standard Agreement Services  
(TIC served as CC)



**Figure 2.** TIN studies that have utilized Standard Agreement services (i.e., TIN FDP-CTSA) wherein a TIC site acted as the study Coordinating Center. Days refer strictly to the contracting process and do not relate to IRB review or budget negotiations. Median days for negotiation: CMV ValEAR = 41; DOSE = 46; SPIRRIT = 151; STRESS = 64; TRANSFORM-HF = 46; SILDI-SAFE = 109.

<b>Table 1. Controversial Terms Negotiated for the ACTA</b>				
<b>Term</b>	<b>Common Position – Institutions</b>	<b>Common Position – Industry</b>	<b>Compromise Position</b>	<b>Changes from the original ACTA to the 2019 updated ACTA</b>
Indemnification/ Limitation of Liability	<ul style="list-style-type: none"> <li>• Limit amount of financial exposure (policies/statutes)</li> <li>• Consider straight negligence too broad</li> <li>• Preference: gross negligence level OR cap</li> </ul>	<ul style="list-style-type: none"> <li>• Institutions should agree to all negligence on their part</li> <li>• Should be managing study activities in a responsible manner</li> </ul>	<ul style="list-style-type: none"> <li>• Institution indemnifies for 3rd party claims directly caused by Institution’s: <ul style="list-style-type: none"> <li>○ Negligence in its conduct of the study</li> <li>○ No cap required</li> <li>○ Subject to limits under applicable law</li> </ul> </li> <li>• Neither party is liable for special, consequential damages <ul style="list-style-type: none"> <li>○ Carving out both parties’ indemnification obligations</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Adds “wrongful acts” of Institution to the exceptions to Sponsor’s obligations of indemnification.</li> <li>• Expands types of immunities under applicable law for Institution to include prohibitions and State Attorney General’s opinions.</li> <li>• Limitation of liability is specific to liability between Parties.</li> </ul>
Confidentiality	<ul style="list-style-type: none"> <li>• Standard to require mutual confidentiality</li> <li>• Policies limiting period of nondisclosure (3 years)</li> </ul>	<ul style="list-style-type: none"> <li>• Often request “one-sided” language</li> <li>• Request broader definition protecting company’s confidential information</li> <li>• Often request longer nondisclosure period (7 years)</li> </ul>	<ul style="list-style-type: none"> <li>• Language “one-sided” - protecting only confidential information from sponsor</li> <li>• Requires marking; however: <ul style="list-style-type: none"> <li>○ Broadly protects information that “by its nature a reasonable person would consider confidential”</li> </ul> </li> <li>• Oral discussions require follow-up in</li> </ul>	<ul style="list-style-type: none"> <li>• Notes that Confidential Information may be disclosed to the Institution by 3<sup>rd</sup> parties (likely CROs) on behalf of the Sponsor.</li> <li>• Removes “reasonable efforts” standard for Sponsor to mark Confidential Information as confidential and instead notes that in the absence of markings, whether a reasonable person familiar with the Study would consider it confidential.</li> <li>• Ties confidentiality person to early termination or completion of the Study identified by the locking of the database instead of just “expiration of this Agreement.”</li> <li>• More specific regarding applicable laws to include local laws, procedures and as required</li> </ul>

			<p>writing</p> <ul style="list-style-type: none"> <li>○ Protection for both parties – summarizing what discussed/disclosed</li> <li>● Period of non-disclosure identified as 5 years</li> </ul>	by the IRB.
Publication	<ul style="list-style-type: none"> <li>● Must retain independent right to publish <ul style="list-style-type: none"> <li>○ tax-exempt, AAHRPP, internal policies</li> <li>○ 30-day review (not approval) by sponsors</li> </ul> </li> <li>● Multicenter/joint publication: Agree to delay of ≤ 12 months after study completion/termination</li> <li>● Institutions request leadership/authorship role</li> </ul>	<ul style="list-style-type: none"> <li>● 30-day review period is tight, but doable</li> <li>● Publication of aggregate data may be &gt; 12 months</li> </ul>	<ul style="list-style-type: none"> <li>● Institution retains independent right to publish <ul style="list-style-type: none"> <li>○ Prior 30-day review by sponsor, with additional delays for sponsor to file patent applications</li> </ul> </li> <li>● However, will not publish site data until: <ul style="list-style-type: none"> <li>○ Multicenter publication is published; or</li> <li>○ 18 months after conclusion, abandonment, or termination of study at all sites; or</li> <li>○ Sponsor confirms in writing that no multicenter publication will occur; whichever occurs first... .</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>● If no multi-center study is published within 18 months of the completion of the Study, Sponsor agrees to provide Institution accesses to “aggregate results pursuant to the Protocol” instead of “aggregate Data.”</li> </ul>
Intellectual Property	<ul style="list-style-type: none"> <li>● IP is result of PI’s knowledge/expertise → retain ownership</li> </ul>	<ul style="list-style-type: none"> <li>● Company-sponsored study; owns product</li> </ul>	<ul style="list-style-type: none"> <li>● Protects both parties’ background IP</li> <li>● Language assigns</li> </ul>	<ul style="list-style-type: none"> <li>● Changes the definition of “Sponsor Inventions” to “enhancements, modifications or improvements to the Study Drug and/or Study</li> </ul>

	<ul style="list-style-type: none"> <li>• Provide exclusive royalty-bearing license <ul style="list-style-type: none"> <li>○ Royalties used to support additional research efforts</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>○ Public companies → obligation to shareholders</li> <li>• Often require assignment of any IP resulting from conduct of study</li> </ul>	<p>ownership to sponsor of IP that uses/incorporates sponsor's product</p> <ul style="list-style-type: none"> <li>• Any "other inventions" determined by U.S. patent law <ul style="list-style-type: none"> <li>○ If an "other invention" should occur → sponsor granted option to an exclusive, royalty-bearing license to Institution's rights in that invention</li> </ul> </li> </ul>	<p>Device" from Inventions that "necessarily use or necessarily incorporate" the Study Drug and/or Device.</p> <ul style="list-style-type: none"> <li>• Institution represents and certifies that All Institution personnel performing the Protocol are obligation to assign to Institution their rights in Inventions to enable Institution to grant Sponsor rights to Inventions that Institution grants under the Agreement.</li> <li>• Institution's internal use rights are simplified to "Shall have a right to use" from "retain a royalty free, irrevocable license to use" Sponsor Inventions or Other Inventions for its own internal noncommercial research, educational and patient care purposes.</li> </ul>
Subject Injury	<ul style="list-style-type: none"> <li>• Sponsor pays for medically necessary services required due to study injuries</li> <li>• Cannot first seek reimbursement from Medicare (per Medicare Secondary Payer Rule) <ul style="list-style-type: none"> <li>○ Rule applied to commercial payers → eliminate patient "discrimination" based on insurance status</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Most often agree to pay for subject injury</li> <li>• Require broader carve-outs limiting obligations</li> </ul>	<ul style="list-style-type: none"> <li>• Agreed on broader carve-outs than institutions usually agree to...</li> <li>• Sponsor agrees to pay for reasonable expenses, but only if not attributable to: <ul style="list-style-type: none"> <li>○ Institution's negligence/willful misconduct or</li> <li>○ The natural progression of an underlying or pre-existing condition or events</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• "Illness" is changed to "medical illness."</li> <li>• Exceptions to Sponsor's subject injury obligation are "directly caused by" instead of "attributable to."</li> <li>• Adds the following exception to Sponsor's subject injury obligation to the extent directly cause by: Institution's failure to adhere to and comply with the specifications of the Protocol and all reasonable written instructions furnished by Sponsor for the use and administration of any {CHOOSE: Study Drug or Study Device} used in the Study, provided that deviations from the Protocol and written instructions resulting from an imminent threat to the health or safety of a Study subject that do not cause the injury to the Study subject will not disqualify Institution from reimbursement under this provision.</li> </ul>

**Table 2. Agreements Developed by the CTSA/Trial Innovation Network as part of the Accelerated Research Agreements Initiative.**

<b>Template Name</b>	<b>Function</b>	<b>Level of Adoption</b>	<b>Last Revision Date</b>
Accelerated Confidential Disclosure Agreement (ACDA)	Support sharing of protocols across participating sites in a multi-center trial	> <b>80</b> research sites (e.g., academic medical centers, universities, hospitals, industry sponsors) have registered	February 2016
Contract Research Organization ACDA (CRO-ACDA)	ACDA adapted for use with Contract Research Organizations (CROs).	**Registration not tracked	February 2016
Federal Demonstration Partnership Clinical Trials Subaward Agreement (FDP-CTSA)	Sub-award template for federally funded clinical trials.	<b>12</b> research sites (e.g., academic medical centers, universities, hospitals, industry sponsors) have registered	July 2016
Contract Research Organization ACTA (CRO-ACTA)	ACTA adapted for use with Contract Research Organizations (CROs).	**Registration not tracked	October 2016
Data Transfer and Use Agreement (CTSA-DTUA)	Developed to facilitate transfer and use of data between sites.	**Registration not tracked	August 2017
Investigator-Initiated ACTA (II-ACTA)	Agreement for use in studies initiated, designed, developed and managed by the sponsor.	**Registration not tracked	August 2017
Trial Innovation Network Confidential Disclosure	Sharing TIN protocols, such that investigators and/or their designees can	>60 CTSA sites and 21	October 2017

Agreement (CDA)	determine whether their site would be interested in participating in a Network Study.	affiliates have executed	
Non-interventional Trial Innovation Network FDP-CTSA Standard Agreement	Derived from the TIN FDP-CTSA Standard Agreement, for use with all research that is observational or does not involve an investigational drug or device but may involve, but is not limited to PHI, clinical testing or procedures, or any planning/lab/clinical service in support of such clinical research.	Sites not required to register for this template, derived from the previously agreed upon terms in the FDP-CTSA Trial Innovation Network Standard Agreement and represents an atypical use case	January 2018
VA-specific Trial Innovation Network Confidential Disclosure Agreement (CDA)	Adapted for VA sites interested in sharing TIN protocols, such that investigators and/or their designees can determine whether their site would be interested in participating in a Network Study.	Sites not required to execute as it is VA-specific and used as a “one off” agreement	January 2018
Accelerated Clinical Trial Agreement (ACTA)	Agreement for use in industry sponsored multi-center study.	> <b>350</b> research sites (e.g., academic medical centers, universities, hospitals, industry sponsors) have registered	December 2019
International ACTA (iACTA)	Agreement for use in industry sponsored multi-center studies involving international sites.	**Registration not tracked	December 2019
Trial Innovation Network FDP-CTSA Standard Agreement	Agreement developed for TIN multi-center federally funded clinical trial sub-awards.	>60 CTSA sites and 10 affiliates have registered	April 2020